Does the media prefer DGX or HSIC?

In the previous week, Quest Diagnostics had 29 more articles in the media than Henry Schein. MarketBeat recorded 37 mentions for Quest Diagnostics and 8 mentions for Henry Schein. Quest Diagnostics' average media sentiment score of 1.38 beat Henry Schein's score of 1.00 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 32 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Henry Schein 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, DGX or MEDP?

Quest Diagnostics has higher revenue and earnings than Medpace. Quest Diagnostics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quest Diagnostics $11.56B 2.34 $992M $9.42 26.03 Medpace $2.53B 6.83 $451.12M $17.06 36.28

Is DGX or MEDP more profitable?

Medpace has a net margin of 17.67% compared to Quest Diagnostics' net margin of 9.18%. Medpace's return on equity of 110.15% beat Quest Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Quest Diagnostics 9.18% 16.01% 7.27% Medpace 17.67% 110.15% 24.84%

Does the media favor DGX or MEDP?

In the previous week, Quest Diagnostics had 4 more articles in the media than Medpace. MarketBeat recorded 37 mentions for Quest Diagnostics and 33 mentions for Medpace. Quest Diagnostics' average media sentiment score of 1.38 beat Medpace's score of 1.05 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 32 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 24 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DGX or AMN?

In the previous week, Quest Diagnostics had 33 more articles in the media than AMN Healthcare Services. MarketBeat recorded 37 mentions for Quest Diagnostics and 4 mentions for AMN Healthcare Services. Quest Diagnostics' average media sentiment score of 1.38 beat AMN Healthcare Services' score of 0.72 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 32 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AMN Healthcare Services 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DGX or LH?

In the previous week, Quest Diagnostics had 27 more articles in the media than Labcorp. MarketBeat recorded 37 mentions for Quest Diagnostics and 10 mentions for Labcorp. Quest Diagnostics' average media sentiment score of 1.38 beat Labcorp's score of 0.73 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 32 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Labcorp 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DGX or CI?

In the previous week, Cigna Group had 5 more articles in the media than Quest Diagnostics. MarketBeat recorded 42 mentions for Cigna Group and 37 mentions for Quest Diagnostics. Cigna Group's average media sentiment score of 1.47 beat Quest Diagnostics' score of 1.38 indicating that Cigna Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 32 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cigna Group 38 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Quest Diagnostics (DGX) Competitors

$245.17 +0.78 (+0.32%)

As of 10:45 AM Eastern

Compare

DGX vs. HSIC, MEDP, AMN, LH, and CI

Should you buy Quest Diagnostics stock or one of its competitors? Quest Diagnostics's main competitors and comparable companies include Henry Schein (HSIC), Medpace (MEDP), AMN Healthcare Services (AMN), Labcorp (LH), and Cigna Group (CI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Quest Diagnostics compare to Henry Schein?

Quest Diagnostics (NYSE:DGX) and Henry Schein (NASDAQ:HSIC) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Quest Diagnostics has higher earnings, but lower revenue than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.56B	2.34	$992M	$9.42	26.03
Henry Schein	$13.18B	0.75	$398M	$3.43	25.97

Quest Diagnostics has a net margin of 9.18% compared to Henry Schein's net margin of 2.96%. Quest Diagnostics' return on equity of 16.01% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
Henry Schein	2.96%	15.97%	5.56%

In the previous week, Quest Diagnostics had 29 more articles in the media than Henry Schein. MarketBeat recorded 37 mentions for Quest Diagnostics and 8 mentions for Henry Schein. Quest Diagnostics' average media sentiment score of 1.38 beat Henry Schein's score of 1.00 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	32 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Henry Schein	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Henry Schein has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

Quest Diagnostics presently has a consensus price target of $235.31, indicating a potential downside of 4.02%. Henry Schein has a consensus price target of $92.93, indicating a potential upside of 4.32%. Given Henry Schein's higher possible upside, analysts plainly believe Henry Schein is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54
Henry Schein	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53

88.1% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 96.6% of Henry Schein shares are owned by institutional investors. 0.9% of Quest Diagnostics shares are owned by insiders. Comparatively, 0.9% of Henry Schein shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Quest Diagnostics beats Henry Schein on 11 of the 17 factors compared between the two stocks.

How does Quest Diagnostics compare to Medpace?

Quest Diagnostics (NYSE:DGX) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Quest Diagnostics currently has a consensus price target of $235.31, suggesting a potential downside of 4.02%. Medpace has a consensus price target of $584.18, suggesting a potential downside of 5.61%. Given Quest Diagnostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Quest Diagnostics is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

Quest Diagnostics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Quest Diagnostics has higher revenue and earnings than Medpace. Quest Diagnostics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.56B	2.34	$992M	$9.42	26.03
Medpace	$2.53B	6.83	$451.12M	$17.06	36.28

88.1% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.9% of Quest Diagnostics shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Quest Diagnostics had 4 more articles in the media than Medpace. MarketBeat recorded 37 mentions for Quest Diagnostics and 33 mentions for Medpace. Quest Diagnostics' average media sentiment score of 1.38 beat Medpace's score of 1.05 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	32 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	24 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has a net margin of 17.67% compared to Quest Diagnostics' net margin of 9.18%. Medpace's return on equity of 110.15% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
Medpace	17.67%	110.15%	24.84%

Summary

Quest Diagnostics beats Medpace on 9 of the 17 factors compared between the two stocks.

How does Quest Diagnostics compare to AMN Healthcare Services?

Quest Diagnostics (NYSE:DGX) and AMN Healthcare Services (NYSE:AMN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

88.1% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are owned by institutional investors. 0.9% of Quest Diagnostics shares are owned by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Quest Diagnostics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

In the previous week, Quest Diagnostics had 33 more articles in the media than AMN Healthcare Services. MarketBeat recorded 37 mentions for Quest Diagnostics and 4 mentions for AMN Healthcare Services. Quest Diagnostics' average media sentiment score of 1.38 beat AMN Healthcare Services' score of 0.72 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	32 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AMN Healthcare Services	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics has a net margin of 9.18% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
AMN Healthcare Services	3.06%	19.92%	5.93%

Quest Diagnostics has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.56B	2.34	$992M	$9.42	26.03
AMN Healthcare Services	$2.73B	0.49	-$95.70M	$2.68	12.91

Quest Diagnostics currently has a consensus target price of $235.31, indicating a potential downside of 4.02%. AMN Healthcare Services has a consensus target price of $31.43, indicating a potential downside of 9.17%. Given Quest Diagnostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Quest Diagnostics is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Summary

Quest Diagnostics beats AMN Healthcare Services on 14 of the 17 factors compared between the two stocks.

How does Quest Diagnostics compare to Labcorp?

Quest Diagnostics (NYSE:DGX) and Labcorp (NYSE:LH) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

In the previous week, Quest Diagnostics had 27 more articles in the media than Labcorp. MarketBeat recorded 37 mentions for Quest Diagnostics and 10 mentions for Labcorp. Quest Diagnostics' average media sentiment score of 1.38 beat Labcorp's score of 0.73 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	32 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Labcorp	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics has a net margin of 9.18% compared to Labcorp's net margin of 6.99%. Labcorp's return on equity of 16.74% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
Labcorp	6.99%	16.74%	7.81%

Quest Diagnostics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by insiders. Comparatively, 0.8% of Labcorp shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Quest Diagnostics has higher earnings, but lower revenue than Labcorp. Quest Diagnostics is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.56B	2.34	$992M	$9.42	26.03
Labcorp	$13.95B	1.97	$876.50M	$12.09	27.98

Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.4%. Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 0.9%. Quest Diagnostics pays out 36.5% of its earnings in the form of a dividend. Labcorp pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has raised its dividend for 14 consecutive years. Quest Diagnostics is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Quest Diagnostics presently has a consensus target price of $235.31, indicating a potential downside of 4.02%. Labcorp has a consensus target price of $330.00, indicating a potential downside of 2.44%. Given Labcorp's stronger consensus rating and higher possible upside, analysts clearly believe Labcorp is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54
Labcorp	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Labcorp beats Quest Diagnostics on 11 of the 20 factors compared between the two stocks.

How does Quest Diagnostics compare to Cigna Group?

Quest Diagnostics (NYSE:DGX) and Cigna Group (NYSE:CI) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

88.1% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 87.0% of Cigna Group shares are owned by institutional investors. 0.9% of Quest Diagnostics shares are owned by insiders. Comparatively, 0.6% of Cigna Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Cigna Group had 5 more articles in the media than Quest Diagnostics. MarketBeat recorded 42 mentions for Cigna Group and 37 mentions for Quest Diagnostics. Cigna Group's average media sentiment score of 1.47 beat Quest Diagnostics' score of 1.38 indicating that Cigna Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	32 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cigna Group	38 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics has a net margin of 9.18% compared to Cigna Group's net margin of 2.27%. Cigna Group's return on equity of 19.75% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
Cigna Group	2.27%	19.75%	5.34%

Quest Diagnostics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Cigna Group has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Cigna Group has higher revenue and earnings than Quest Diagnostics. Cigna Group is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.56B	2.34	$992M	$9.42	26.03
Cigna Group	$274.90B	0.27	$5.96B	$24.17	11.50

Quest Diagnostics currently has a consensus price target of $235.31, indicating a potential downside of 4.02%. Cigna Group has a consensus price target of $339.45, indicating a potential upside of 22.10%. Given Cigna Group's stronger consensus rating and higher probable upside, analysts plainly believe Cigna Group is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54
Cigna Group	0 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.68

Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.4%. Cigna Group pays an annual dividend of $6.24 per share and has a dividend yield of 2.2%. Quest Diagnostics pays out 36.5% of its earnings in the form of a dividend. Cigna Group pays out 25.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has increased its dividend for 14 consecutive years and Cigna Group has increased its dividend for 5 consecutive years. Cigna Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Cigna Group beats Quest Diagnostics on 11 of the 20 factors compared between the two stocks.

Get Quest Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DGX vs. The Competition

Export

Metric	Quest Diagnostics	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$27.03B	$9.92B	$7.29B	$24.25B
Dividend Yield	1.43%	2.55%	2.54%	3.71%
P/E Ratio	26.00	34.52	271.88	30.32
Price / Sales	2.34	4.86	607.59	19.83
Price / Cash	16.11	24.64	29.03	19.80
Price / Book	3.78	5.40	11.21	4.91
Net Income	$992M	$309.96M	$3.47B	$1.07B
7 Day Performance	4.24%	0.73%	1.54%	0.06%
1 Month Performance	7.51%	2.06%	6.89%	3.11%
1 Year Performance	36.13%	15.67%	23.94%	14.65%

Quest Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DGX Quest Diagnostics	4.2598 of 5 stars	$245.17 +0.3%	$235.31 -4.0%	+35.7%	$27.03B	$11.56B	26.00	57,000	Positive News
HSIC Henry Schein	3.1687 of 5 stars	$89.52 -0.3%	$92.27 +3.1%	+27.2%	$10.00B	$13.18B	26.10	25,000	Analyst Upgrade
MEDP Medpace	3.5446 of 5 stars	$597.12 +3.2%	$584.18 -2.2%	+33.9%	$16.15B	$2.53B	35.00	6,200	Positive News Insider Trade
AMN AMN Healthcare Services	1.7642 of 5 stars	$34.46 -0.1%	$31.43 -8.8%	+66.7%	$1.34B	$2.73B	12.86	2,664
LH Labcorp	4.2686 of 5 stars	$323.18 +1.6%	$330.00 +2.1%	+20.9%	$25.80B	$13.95B	26.73	71,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DGX) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quest Diagnostics (DGX) Competitors

DGX vs. HSIC, MEDP, AMN, LH, and CI

How does Quest Diagnostics compare to Henry Schein?

Summary

How does Quest Diagnostics compare to Medpace?

Summary

How does Quest Diagnostics compare to AMN Healthcare Services?

Summary

How does Quest Diagnostics compare to Labcorp?

Summary

How does Quest Diagnostics compare to Cigna Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DGX vs. The Competition

Quest Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quest Diagnostics (DGX) Competitors

DGX vs. HSIC, MEDP, AMN, LH, and CI

How does Quest Diagnostics compare to Henry Schein?

Which has better earnings & valuation, DGX or HSIC?

Is DGX or HSIC more profitable?

Does the media prefer DGX or HSIC?

Which has more risk & volatility, DGX or HSIC?

Do analysts prefer DGX or HSIC?

Do institutionals & insiders believe in DGX or HSIC?

Summary

How does Quest Diagnostics compare to Medpace?

Do analysts recommend DGX or MEDP?

Which has more volatility and risk, DGX or MEDP?

Which has stronger earnings and valuation, DGX or MEDP?

Do institutionals and insiders hold more shares of DGX or MEDP?

Does the media favor DGX or MEDP?

Is DGX or MEDP more profitable?

Summary

How does Quest Diagnostics compare to AMN Healthcare Services?

Do institutionals & insiders believe in DGX or AMN?

Which has more risk & volatility, DGX or AMN?

Does the media favor DGX or AMN?

Is DGX or AMN more profitable?

Which has better valuation and earnings, DGX or AMN?

Do analysts rate DGX or AMN?

Summary

How does Quest Diagnostics compare to Labcorp?

Does the media prefer DGX or LH?

Is DGX or LH more profitable?

Which has more risk and volatility, DGX or LH?

Do institutionals and insiders hold more shares of DGX or LH?

Which has stronger valuation and earnings, DGX or LH?

Is DGX or LH a better dividend stock?

Do analysts prefer DGX or LH?

Summary

How does Quest Diagnostics compare to Cigna Group?

Do insiders and institutionals believe in DGX or CI?

Does the media favor DGX or CI?

Is DGX or CI more profitable?

Which has more risk and volatility, DGX or CI?

Which has preferable earnings and valuation, DGX or CI?

Do analysts prefer DGX or CI?

Is DGX or CI a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DGX vs. The Competition

Quest Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools